Prenetics Global (NASDAQ:PRE) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Prenetics Global (NASDAQ:PRE) received a "sell (D-)" rating from Weiss Ratings, indicating a negative outlook on the stock.
• The company reported a negative EPS of ($0.82) for the most recent quarter, with a revenue of $17.68 million and a significant negative net margin of 87.92%.
• Despite the unfavorable rating from Weiss, Wall Street Zen upgraded the stock to a "hold," suggesting mixed sentiments among analysts.

Prenetics Global (NASDAQ:PRE - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Prenetics Global to a "hold" rating in a research note on Saturday, July 5th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $9.00.

Prenetics Global Stock Up 3.0%

NASDAQ PRE opened at $14.81 on Wednesday. The stock has a market cap of $192.31 million, a PE ratio of -3.71 and a beta of 0.34. The business has a 50 day moving average price of $9.74 and a two-hundred day moving average price of $7.72. Prenetics Global has a fifty-two week low of $3.09 and a fifty-two week high of $15.45.

Prenetics Global (NASDAQ:PRE - Get Free Report) last released its earnings results on Friday, September 12th. The company reported ($0.82) EPS for the quarter. The business had revenue of $17.68 million for the quarter. Prenetics Global had a negative net margin of 87.92% and a negative return on equity of 31.05%. Prenetics Global has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Prenetics Global will post -3.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Prenetics Global

An institutional investor recently raised its position in Prenetics Global stock. Nomura Holdings Inc. boosted its stake in Prenetics Global Limited (NASDAQ:PRE - Free Report) by 3.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 333,528 shares of the company's stock after buying an additional 10,576 shares during the period. Nomura Holdings Inc. owned 2.73% of Prenetics Global worth $1,307,000 as of its most recent SEC filing. Institutional investors own 25.01% of the company's stock.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.